Visikol Grand Opening

CRO Visikol Expands Hampton Footprint by 11K Square Feet

August 1, 2022

To meet growing demand, Visikol said July 28 that it expanded its Hunterdon County facility with new lab and office space.

The 11,000-square-foot addition sits adjacent to the company’s current space at the Shelbourne Building in Hampton, allowing it to continue growing while keeping the team under one roof.

Visikol is a contract research services company (CRO) that works with pharmaceutical and biotech firms to accelerate their drug discovery and development programs. The company was spun out from Rutgers University in 2016. According to Visikol, it currently counts the top 20 pharmaceutical companies among its clients and has helped in the discovery and development of dozens of drug programs.

“It has been amazing to see Visikol grow from a small closet at Rutgers into a leading contract research services company that is shaping the way that research is conducted,” Visikol CEO and Co-founder Michael Johnson said in a statement. “This additional space will allow us to better serve the needs of our clients and to continually expand the breadth and depth of our contract research services offering.”

In particular, over the past two years the business has grown as the advanced tissue imaging and advanced cell culture services offered by Visikol have seen more widespread adoption. According to the firm, its multiplex tissue imaging is now a “go-to” tool for researchers working on immuno-oncology therapeutics and those working to understand the part the immune system plays in “the tumor micro-environment.”

End-to-end services include: 3D tissue imaging, multiplex tissue imaging, digital pathology, high content imaging, 2D cell culture assays, 3D cell culture assays and ex vivo tissue slice assays. The company says it excels at turning tissues into “actionable insights” and in closing the gap between in vitro assays and in vivo results using best-in-class cell culture models.

Visikol initially made the move to Hampton in 2020.

Read the Article on NJ Biz
PREVAll NewsnEXT